 
 
Official Title:  Pi[INVESTIGATOR_409390] -Release 
Tacrolimus (ENVARSUS XR) to Immediate -Release Tacrolimus in Lung 
Transplant Recipi[INVESTIGATOR_409391] : [STUDY_ID_REMOVED]  
Study Number:  19-[ZIP_CODE]  
Document Type:   Study Protocol and Statistical Analysis Plan  
Date of the 
Document:  •  December 21, 2021  
 
 
  Page i 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_409427][INVESTIGATOR_409392] -
RELEASE  TACROLIMUS (ENVARSUS XR) TO IMMEDIATE -RELEASE  
TACROLIMUS IN LUNG TRANSPLANT RECIPI[INVESTIGATOR_409393] : 
 Luis F Angel, MD  
Professor of Medicine and Cardiothoracic Surgery  
Medical Director, Lung Transplant Program  
[ADDRESS_516279], HCC Suite 7A  
[LOCATION_001], NY [ZIP_CODE]  
[PHONE_8451]  
[EMAIL_7794]  
Additional Investigators : Co-investigators:  
Tyler Lewis, PharmD ([EMAIL_7795])  
Zachary Kon, MD (z achary. [EMAIL_7796])  
Melissa Lesko, DO ( [EMAIL_7797] ) 
Darya Rudym, MD ( [EMAIL_7798] 
Kimberly Sureau, DNP ([EMAIL_7799])  
Stephanie Chang, MD ([EMAIL_7800])  
NYULMC Study  Number:  i19-[ZIP_CODE]   
Funding Sponsor:  Veloxis Pharmaceuticals Inc.  
[ADDRESS_516280], Cary, NC [ZIP_CODE]  
[PHONE_8452]  
IND/IDE Number:  None  
Regulatory Sponsor :  None  
Study Product:  Extended -release Tacrolimus (Envarsus XR)  
Study Product Provider:  Veloxis Pharmaceuticals, Inc, Cary, North Carolina  
ClinicalTrials.gov 
Number                 To be assigned.  
 
Initial version:  January 28, [ADDRESS_516281] Addendum: July 6, 2020  
2nd Addendum: July 23, [ADDRESS_516282] Addendum: October 30, 2020  
4th Addendum: November 30, 2020  
5th Addendum: January 27, 2021  
6th Addendum: March 25, 2021  
7th Addendum: May 18, 2021  
8th Addendum: December 10, 2021
  Page ii 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_409428] (45 CFR Part 46), 21 CFR Parts 50, 56, 312, and 812 as applicable, any other applicable US government research regulations , and institutional research policies and proce dures . The International 
Conference on Harmonis ation (“ICH”) Guideline for Good Clinical Practice (“GCP”) (sometimes referred to 
as “ICH -GCP” or “E6”) will be applied only to the extent that it is compatible with FDA and DHHS regulations.  
The Principal Investigator [INVESTIGATOR_7433], or changes to the protocol will take place without prior agreement from the sponsor and documented approval from the Institutional Review Board (IRB), except where necessary to eliminate an immediate hazard(s) to the trial participants. All personnel 
involved in the conduct of this study have completed Human Subjects Protection Training.  
  
Study number:  i19-[ZIP_CODE]   Page iii 
Version: December 10, [ADDRESS_516283] OF ABBREVIATION S......................................................................................................................... VI 
PROTOCOL SUMMARY  .............................................................................................................................. 1 
SCHEMATIC OF STUDY DESIGN  ............................................................................................................... 2 
1 KEY ROLES  ............................................................................ ERROR! BOOKMARK NOT DEFINED.  
2 INTRODUCTION, BACKGROUND INFORMATION AND SCIENTIFIC RATIONAL E ....................... 4 
2.1 BACKGROUND INFORMATION AND RELEVANT LITERATURE  ................................................................ 4 
2.2 NAME [CONTACT_409451]  .............................................................. 5 
2.2.1  Preclinical Data ........................................................................................................................ 6 
2.2.2  Clinical Data to Date  ................................................................................................................ 6 
2.2.3  Dose Rationale (if applicable)  ................................................................................................. 6 
2.3 RATIONALE  .................................................................................................................................... 6 
2.4 POTENTIAL RISKS & BENEFITS  ........................................................................................................ 7 
2.4.1  Known Potential Risks  ............................................................................................................. 7 
2.4.2  Known Potential Benefits  ........................................................................................................ 7 
3 OBJECTIVES AND PURPO SE ........................................................................................................... 7 
3.1 PRIMARY OBJECTIVE  ...................................................................................................................... 7 
3.2 SECONDARY OBJECTIVES (IF APPLICABLE ) ...................................................................................... 7 
4 STUDY DESIGN AND ENDPOINTS .................................................................................................... 7 
4.1 DESCRIPTION OF STUDY DESIGN  .................................................................................................... 7 
4.2 STUDY ENDPOINTS ......................................................................................................................... 7 
4.2.1  Primary Study Endpoints  ......................................................................................................... 7 
4.2.2  Secondary Study Endpoints  .................................................................................................... 7 
4.2.3  Exploratory Endpoints  ............................................................. Error! Bookmark not defined.  
5 STUDY ENROLLMENT AND WITHDRAWAL  .................................................................................... 8 
5.1 INCLUSION CRITERIA  ...................................................................................................................... 8 
5.2 EXCLUSION CRITERIA  ..................................................................................................................... 8 
5.3 VULNERABLE POPULATIONS  ........................................................................................................... 8 
5.4 STRATEGIES FOR RECRUITMENT AND RETENTION  ............................................................................ 8 
5.5 DURATION OF STUDY PARTICIPATION  .............................................................................................. 8 
5.6 TOTAL NUMBER OF PARTICIPANTS AND SITES .................................................................................. 9 
5.7 PARTICIPANT WITHDRAWAL OR TERMINATION  .................................................................................. 9 
5.7.1  Reasons for Withdrawal or Termination  .................................................................................. 9 
5.7.2  Handling of Participant Withdrawals or Termination  ............................................................... 9 
5.8 PREMATURE TERMINATION OR SUSPENSION OF STUDY  .................................................................... 9 
6 STUDY AGENT (STUDY DRUG, DEVICE, BIOLOGI C, VACCINE ETC.) AND/OR PROCEDURAL 
INTERVENTION  ......................................................................................................................................... 10 
6.1 STUDY AGENT (S) AND CONTROL DESCRIPTION  .............................................................................. [ADDRESS_516284] Storage and Stability  ................................................................................................ 10 
6.1.4  Preparation  ............................................................................................................................ 10 
6.1.5  Dosing and Administration  .................................................................................................... 10 
6.1.6  Route of Administration  ......................................................................................................... 11 
6.1.7  Starting Dose and Dose Escalation Schedule  ...................................................................... 11 
6.1.8  Dose Adjustments/Modifications/Delays  ............................................................................... 11 
6.1.9  Duration of Therapy  ............................................................................................................... 11 
Study number:  i19-[ZIP_CODE]   Page iv 
Version: December 10, 2021    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_4530]  6.1.10  Tracking of Dose  ............................................................................................................... 11 
6.1.11  Device  Specific Considerations  .......................................... Error! Bookmark not defined.  
6.2 STUDY AGENT ACCOUNTABILITY PROCEDURES  ............................................................................. 11 
6.3 STUDY BEHAVIORAL OR SOCIAL INTERVENTION (S) ......................... ERROR ! BOOKMARK NOT DEFINED . 
6.3.1  Administration of Intervention  .................................................. Error! Bookmark not defined.  
6.3.2  Procedures for Training Interventionalists and Monitoring Intervention Fidelity  ............. Error! 
Bookmark not defined.  
6.3.[ADDRESS_516285] Compliance with Study Intervention  ................................................ 11 
6.4 STUDY PROCEDURAL INTERVENTION (S) DESCRIPTION  ................... ERROR ! BOOKMARK NOT DEFINED . 
6.4.1  Administration of Procedural Intervention  ............................... Error! Bookmark not defined.  
6.4.2  Procedures for Training of Clinicians on Procedural Intervention Error! Bookmark not 
defined.  
6.4.3  Assessment of Clinician and/or Participant Compliance with Study Procedural Intervention
 Error! Bookmark not defined.  
7 STUDY PROCEDURES AND SCHEDULE  ....................................................................................... 11 
7.1 STUDY PROCEDURES /EVALUATIONS  ............................................................................................. [ADDRESS_516286] of Care Study Procedures  ..................................................................................... 12 
7.2 LABORATORY PROCEDURES /EVALUATIONS  ................................................................................... 12 
7.2.1  Clinical Laboratory Evaluations  ............................................................................................. 12 
7.2.2  Other Assays or Procedures  ................................................... Error! Bookmark not defined.  
7.2.3  Specimen Preparation, Handling, and Storage  ....................... Error! Bookmark not defined.  
7.2.4  Specimen Shipment  ................................................................ Error! Bookmark not defined.  
7.3 STUDY SCHEDULE  ........................................................................ ERROR ! BOOKMARK NOT DEFINED . 
7.3.1  Screening  ................................................................................ Error! Bookmark not defined.  
7.3.2  Enrollment/Baseline  ................................................................ Error! Bookmark not defined.  
7.3.3  Intermediate Visits  ................................................................... Error! Bookmark not defined.  
7.3.4  Final Study Visit  ....................................................................... Error! Bookmark not defined.  
7.3.5  Withdrawal/Early Termination Visit .......................................... Error! Bookmark not defined.  
7.3.6  Unscheduled Visit  .................................................................... Error! Bookmark not defined.  
7.4 CONCOMITANT MEDICATIONS , TREATMENTS , AND PROCEDURES  .................................................... 12 
7.5 JUSTIFICATION FOR SENSITIVE PROCEDURES  ................................ ERROR ! BOOKMARK NOT DEFINED . 
7.5.1  Precautionary  Medications, Treatments, and Procedures  .................................................... 12 
7.6 PROHIBITED MEDICATIONS , TREATMENTS , AND PROCEDURES  ........................................................ 13 
7.7 PROPHYLACTIC MEDICATIONS , TREATMENTS , AND PROCEDURES  ... ERROR ! BOOKMARK NOT DEFINED . 
7.8 RESCUE MEDICATIONS , TREATMENTS , AND PROCEDURES  ............. ERROR ! BOOKMARK NOT DEFINED . 
7.9 PARTICIPANT ACCESS TO STUDY AGENT AT STUDY CLOSURE  ........................................................ 13 
8 ASSES SMENT OF SAFETY  ............................................................................................................. 13 
8.1 SPECIFICATION OF SAFETY PARAMETERS  ...................................................................................... 13 
8.1.1  Definition of Adverse Events (AE)  ......................................................................................... 13 
8.1.2  Definition of Serious Adverse Events (SAE)  ......................................................................... 13 
8.1.3  Definition of Unanticipated Problems (UP)  ............................................................................ 14 
8.2 CLASSIFICATION OF AN ADVERSE EVENT  ....................................................................................... 14 
8.2.1  Severity of Event  ................................................................................................................... 14 
8.2.2  Relationship to Study Agent  .................................................................................................. 14 
8.2.3  Expectedness  ........................................................................................................................ 15 
8.3 TIME PERIOD AND FREQUENCY FOR EVENT ASSESSMENT AND FOLLOW -UP .................................... 15 
8.4 REPORTING PROCEDURES – NOTIFYING THE IRB .......................................................................... 16 
8.4.1  Adverse Event Reporting  ...................................................................................................... 16 
8.4.2  Serious Adverse Event Reporting  ......................................................................................... 16 
8.4.3  Unanticip ated Problem Reporting  ......................................................................................... 16 
8.4.4  Reporting of Pregnancy  ......................................................................................................... 16 
8.5 REPORTING PROCEDURES – NOTIFYING THE STUDY SPONSOR  ...................................................... 16 
8.6 REPORTING PROCEDURES – NOTIFYING THE FDA ......................... ERROR ! BOOKMARK NOT DEFINED . 
8.7 REPORTING PROCEDURES – PARTICIPATING INVESTIGATORS  ......... ERROR ! BOOKMARK NOT DEFINED . 
Study number:  i19-[ZIP_CODE]   Page v 
Version: December 10, 2021    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_4530]  8.8 STUDY HALTING RULES ................................................................ ERROR ! BOOKMARK NOT DEFINED . 
8.9 SAFETY OVERSIGHT  ..................................................................................................................... 17 
9 CLINICAL MONITORING  .................................................................................................................. 17 
10 STATISTICAL CONSIDER ATIONS  .................................................................................................. 17 
10.1  STATISTICAL AND ANALYTICAL PLANS (SAP)  ................................................................................. 17 
10.2  STATISTICAL HYPOTHESES  ........................................................................................................... 18 
10.3  ANALYSIS DATASETS  .................................................................................................................... 18 
10.4  DESCRIPTION OF STATISTICAL METHODS  ...................................................................................... 18 
10.4.1  General Approach  ............................................................................................................. 18 
10.4.2  Analysis of the Primary Efficacy Endpoint(s)  .................................................................... 18 
10.4.3  Analysis of the Secondary Endpoint(s)  ............................................................................. 18 
10.4.4  Safety Analyses  ................................................................................................................ 18 
10.4.5  Adherence and Retention Analyses  .................................................................................. 18 
10.4.6  Baseline Descriptive Statistics  .......................................................................................... 19 
10.4.7  Planned Interim Analysis  .................................................................................................. 19 
10.4.8  Addition al Sub- Group Analyses  .......................................... Error! Bookmark not defined.  
10.4.9  Multiple Comparison/Multiplicity  .......................................... Error! Bookmark not defined.  
10.4.10  Tabulation of Individual Response Data  ............................. Error! Bookmark not defined.  
10.4.11  Exploratory Analyses  .......................................................... Error! Bookmark not defined.  
10.5  SAMPLE SIZE ............................................................................................................................... 19 
10.6  MEASURES TO MINIMIZE BIAS ....................................................... ERROR ! BOOKMARK NOT DEFINED . 
10.6.1  Enrollment/Randomization/Masking Procedures  ................ Error! Bookmark not defined.  
10.6.2  Evaluation of Success of Blinding  ....................................... Error! Bookmark not defined.  
10.6.3  Breaking the Study Blind/Participant Code  ......................... Error! Bookmark not defined.  
11 SOURCE DOCUMENTS AND ACCESS TO SOURCE DA TA/DOCUMENTS  ................................. 19 
12 QUALITY ASSURANCE AN D QUALITY CONTROL  ....................................................................... 20 
13 ETHICS/PROTECTION OF  HUMAN SUBJECTS  ............................................................................. [ADDRESS_516287]  ..................................................................................................... 20 
13.3  INFORMED CONSENT PROCESS  .................................................................................................... 20 
13.3.1  Consent/Assent and Other Informational Documents Provided to Participants  ............... [ADDRESS_516288] KEEPI[INVESTIGATOR_1645]  ................................................................................... 22 
14.1  DATA COLLECTION AND MANAGEMENT RESPONSIBILITIES  .............................................................. 22 
14.2  STUDY RECORDS RETENTION  ....................................................................................................... 22 
14.3  PROTOCOL DEVIATIONS  ............................................................................................................... 22 
14.4  PUBLICATION AND DATA SHARING POLICY  ..................................................................................... 23 
15 STUDY FINANCES  ............................................................................................................................ 23 
15.1  FUNDING SOURCE  ........................................................................................................................ 23 
15.2  COSTS TO THE PARTICIPANT  ......................................................................................................... 23 
15.3  PARTICIPANT REIMBURSEMENTS OR PAYMENTS  ............................ ERROR ! BOOKMARK NOT DEFINED . 
[ADDRESS_516289]  POLICY  .................................................................................................. 24 
18 REFERENCES  ................................................................................................................................... 24 
Study number:  i19-[ZIP_CODE]   Page vi 
Version: December 10, [ADDRESS_516290] of Abbreviations  
 
ACR  Acute Cellular Rejection  
AE Adverse Event/Adverse Experience  
AMR  Antibody -mediated Rejection  
CFR Code of Federal Regulations  
CKD  Chronic Kidney Disease  
CRF Case Report Form  
CSOC  Clinical Study Oversight Committee  
DCC  Data Coordinating Center  
DHHS  Department of Health and Human Services  
DSA Donor -Specific Antibody  
DSMB  Data and Safety Monitoring Board  
FFR Federal Financial Report  
FWA  Federalwide Assurance  
GCP  Good Clinical Practice  
HIPAA  Health Insurance Portability and Accountability Act  
ICF Informed Consent Form  
ICH International Conference on Harmonisation  
IR Immediate Release  
IRB Institutional Review Board  
ISM Independent Safety Monitor  
MOP  Manual of Procedures  
N Number (typi[INVESTIGATOR_33891])  
NIH National Institutes of Health  
OHRP  Office for Human Research Protections  
OHSR  Office of Human Subjects Research  
PI [INVESTIGATOR_251961]/Serious Adverse Experience  
SOP  Standard Operating Procedure  
US [LOCATION_002]  
Study number:  i19-[ZIP_CODE]   Page 1 
Version: December 10, 2021    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_409429][INVESTIGATOR_409394] -release Tacrolimus 
(ENVARSUS XR) to immediate- release Tacrolimus in lung transplant 
recipi[INVESTIGATOR_409395] a lung transplant will be enrolled. All patients will 
undergo lung transplantation with standard post -operative management, 
including triple immunosuppression. As soon as the patient is deemed 
appropriate to take medications via the oral route, they will be converted from IR tacrolimus to Envarsus XR. Patients will be followed per site’s standard of 
care.  
Phase  Pi[INVESTIGATOR_409396] a lung transplant. To compare the impact of tacrolimus formulation on CKD, ACR, AMR, and de novo DSA within the first year post -
lung transplant.  
Methodology  Single -center, open- label study  
Endpoint  Incidence of CKD, ACR, AMR, and de novo DSA in the first year post-lung 
transplant  
Study Duration  Two years  
Participant Duration  One year  
Duration of IP administration  One year  
Population  Adult patients undergoing lung transplantation  
Study Sites  NYU Langone Hospi[INVESTIGATOR_409397] ( 20 patients who received IR tacrolimus and 40 patients who 
will receive Envarsus XR)  
Description of Study Agent/Procedure  Lung transplantation will be performed per standard -of-care techniques. All 
post-transplant management, including initial triple immunosuppression, will 
be carried out per standard of care. Once the patient is able to take medications via the oral route, t hey will be converted to Envarsus XR, which 
will be maintained for the first year post -lung transplant.  
Reference Therapy  IR tacrolimus  
Key Procedures  Patients in the Prospective Cohort will receive lung transplantation and post -
operative management per standard protocol, including frequency of laboratory assays, surveillance bronchoscopy, and DSA assessment by 
[CONTACT_25505] -antigen bead assay.  
Statistical Analysis  Categorical variables will b e compared using chi -square test or Fisher’s exact 
test, as appropriate. Continuous variables will be compared using the Mann-
Whitney U test for nonparametric data.  
 
  
Study number:  i19-[ZIP_CODE]   Page 2 
Version: December 10, 2021    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_409430] 1  n=40  Envarsus XR to be 
initiated once 
patient is tolerating 
oral medications  
IR tacrolimus 
(historical control)  ARM 2  n=20  Historical cohort of 
patients maintained 
on IR tacrolimus 
following transplant  
  
  
Study number:  i19-[ZIP_CODE]   Page 3 
Version: December 10, 2021    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_4530]  1 Key Roles  
 
Principal Investigator :  
[INVESTIGATOR_409398], MD  
Professor of Medicine and Cardiothoracic Surgery  
Director, Lung Transplant Program  
[ADDRESS_516291], HCC Suite 7A  
[LOCATION_001], NY [ZIP_CODE]  
[PHONE_8451]  
[EMAIL_7801] 
 
Co-I nvestigator s: 
Tyler Lewis, PharmD  
Clinical Assistant Professor, Department of Cardiothoracic Surgery  
Clinical Pharmacotherapy Specialist, Lung Transplant  
Clinical Pharmacy Manager, Solid Organ Transplant  
[ADDRESS_516292], GBH SC2- 097 
[LOCATION_001], NY [ZIP_CODE]  
[PHONE_8453]  
[EMAIL_7802] 
 
Zachary Kon, MD  
Assistant Professor of Cardiothoracic Surgery  
Surgical Director, Lung Transplant Program and Mechanical Circulatory Support  
NYU Langone Cardiothoracic Surgery Associates  
[ADDRESS_516293], Suite 9V  
[LOCATION_001], NY [ZIP_CODE]  
[PHONE_8454]  
[EMAIL_7803] 
 Melissa Lesko, DO  
Instructor, Department of Medicine  
NYU Langone Transplant Institute  
[ADDRESS_516294], HCC12  
[LOCATION_001], NY [ZIP_CODE]  
[PHONE_8455]  
[EMAIL_7804]  
 Darya Rudym, MD  
Clinical Assistant Professor, Department of Medicine  
NYU Langone Transplant Institute  
[ADDRESS_516295], HCC12  
[LOCATION_001], NY [ZIP_CODE]  
[PHONE_8455]  
[EMAIL_7805]  
 Stephanie Chang, MD  
Assistant Professor, Department of Cardiothoracic Surgery NYU Langone Cardiothoracic Surgery Associates  
[ADDRESS_516296], Suite 9V  
[LOCATION_001], NY [ZIP_CODE]  
[PHONE_8456]  
[EMAIL_7806]  
  
Study number:  i19-[ZIP_CODE]   Page 4 
Version: December 10, [ADDRESS_516297], HCC12  
[LOCATION_001], NY [ZIP_CODE]  
646- 501-8996  
 
Research Coordinators :  
Elaina Weldon, MSN, ACNP -BC 
Transplant Research Nurse Practitioner  
NYU Langone Transplant Institute  
[ADDRESS_516298], 4th Floor  
[LOCATION_001], NY [ZIP_CODE]  
[PHONE_8457]  
[EMAIL_7807]  
 
Cecilia Deterville, MS, CCRC  
Senior Clinical Research Coordinator  
NYU Langone Transplant Institute  
[ADDRESS_516299], 4th Floor  
[LOCATION_001], NY [ZIP_CODE]  
[PHONE_8458]  
[EMAIL_7808]  
 
2 Introduction, Background Information and Scientific Rationale  
 
2.1 Background Information and Relevant Literature  
Lung transplantation remains the definitive cure for many end- stage lung diseases. Despi[INVESTIGATOR_409399], morbidity and mortality remain unacceptably high.1 Chronic lung 
allograft dysfunction (CLAD) is the major barrier to long -term survival in lung transplant recipi[INVESTIGATOR_840].2  The 
risk for CLAD is heterogenous, yet acute cellular rejection (ACR) has consistently been identified as a risk factor for the development of CLAD, with just one epi[INVESTIGATOR_44715] A1 ACR portending a higher likelihood of 
CLAD.
3-[ADDRESS_516300] -lung transplant may therefore reduce the incidence of 
CLAD.  
 Tacrolimus is the backbone of rejection prevention following lung transplantation. Interpatient variability in tacrolimus pharmacokinetics make achieving consistent systemic exposure challenging and necessitate the use of therapeutic drug monitoring (TDM).
[ADDRESS_516301] deviation (SD). In 
their cohort, the risk of ACR was increased by 23% for every [ADDRESS_516302] -transplant, but was similar between months 
6-12 and 12- 24. Again it was observed that for each 1 unit increase in tacrolimus SD the risk of CLAD 
and death was significantly increased.8 Recent data in lung transplant recipi[INVESTIGATOR_409400]-in-therapeutic range for tacrolimus by 10% within the first year post -transplant reduced the burden of 
ACR by 54%.9 Similar data was recently published in heart transplant recipi[INVESTIGATOR_409401] C0 levels.10 Taken 
Study number:  i19-[ZIP_CODE]   Page 5 
Version: December 10, [ADDRESS_516303] rejection and that trends in trough levels should be monitored as well.  
 Envars us XR is a once- daily, extended- release formulation of tacrolimus that utilizes MeltDose 
technology optimize the pharmacokinetics of tacrolimus.
11,12 Pharmacokinetic studies in kidney transplant 
recipi[INVESTIGATOR_409402] -to-trough levels, decreased Cmax and increased 
Tmax for Envarsus XR as compared to IR tacrolimus. Additionally, bioavailability was improved with a stronger correlation between trough concentration (C
0) and AUC.13-[ADDRESS_516304] to compare the efficacy and safety of IR tacrolimus with conversion to Envarsus XR in kidney transplant recipi[INVESTIGATOR_840]. The primary efficacy endpoint was a composite of death, graft failure, biopsy -
proven acute rejection (BPAR), or loss to follow -up over a 12 month period. Tacrolimus TDD was 
decreased by 30% in patients converted to Envarsus XR. There was a significant decrease in TDD with conversion to Envarsus XR despi[INVESTIGATOR_409403]. The efficacy endpoint was similar between groups (2.5 vs. 2.5%, p>0.999). Additionally, there were no differences between individual components of 
the composite endpoint. A subsequent prospective, double- blind, double- dummy, multicenter, phase III 
comparison of IR tacolimus and de novo Envarsus XR was conducted to demonstrate non- inferiority at 
24-months follow -up. Treatment failure defined as death, transplant failure, BPAR, or loss to follow -up 
was similar between the two drugs (Envarsus XR 23.1%, IR tacrolimus 27.3%) and well below the 10% 
non-inferiority margin. There was no significant difference in safety outcomes, including changes in 
estimated glomerular filtration rate (eGFR) and serum creatinine (Scr) was similar between groups. 
Certain subgroup populations (Afr ican-American race, age > 65, female gender) demonstrated trends 
towards significant efficacy benefit with Envarsus XR, however these groups were too small reach 
statistical significance.
16 
 A phase II study comparing the pharmacokinetics of Envarsus XR to another unique prolonged- release 
tacrolimus formulation (Advagraf) is the only published experience to date in lung transplant recipi[INVESTIGATOR_840]. This open- label, single- arm, prospective evaluated 20 lung transplant recipi[INVESTIGATOR_409404] a conversion dose of 1:0.7. Mean AUC was similar despi[INVESTIGATOR_409405] (5.05 vs. 3.36 mg, p=0.[ZIP_CODE]). Time to peak concentration was prolonged with Envarsus XR compared to Advagraf (325 vs. 125 minutes, p<0.001). Adverse events did not differ between the two formulations over the 6 month follow -up, and no 
major adverse events were considered related to the tacrolimus formulation or required withdrawal  of 
therapy.
17 It is unknown if Envarsus XR would improve immunologic outcomes in lung transplant 
recipi[INVESTIGATOR_409406] a stable pharmacokinetic profile and minimizing variability.  
 Currently at NYU Langone Health (NYULH), our practice has been to convert lung transplant recipi[INVESTIGATOR_409407]. The only deterrent to inpatient use is the 
lack of availability on NYULH formulary. We have however experienced subtherapeutic tacrolimus C
[ADDRESS_516305] -transplant period.  
2.2 Name [CONTACT_409452] (tacrolimus extended- release tablets)  
Manufactured by [CONTACT_409431], North Rhine- Westphalia, [LOCATION_013]  
Manufactured for Veloxis Pharmaceuticals, Cary, NC  
 
Envar sus XR is an FDA -approved drug for the prophylaxis of organ rejection in de novo kidney transplant 
patients or in kidney transplant patients converted from IR tacrolimus when used with other immunosuppressants.  
 Envarsus XR is a novel extended- release formulation of tacrolimus created using MeltDose technology.  
Study number:  i19-[ZIP_CODE]   Page 6 
Version: December 10, 2021    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_4530]  2.2.1  Preclinical Data  
Compared to IR tacrolimus, Envarsus XR has improved bioavailability, a lower peak concentration (C max), 
similar area -under -the-concentration- time curve (AUC) despi[INVESTIGATOR_409408] (TDD).18 
2.2.2  Clinical Data to Date  
A phase II study comparing the pharmacokinetics of Envarsus XR to another unique prolonged- release 
tacrolimus formulation (Advagraf) is the only experience to date in lung transplant recipi[INVESTIGATOR_840]. This open-
label, single -arm, prospective evaluated 20  lung transplant recipi[INVESTIGATOR_409409] a conversion dose of 1:0.7. Mean AUC was similar despi[INVESTIGATOR_409405] (5.05 vs. 3.36 mg, p=0.[ZIP_CODE]). Time to peak 
concentration was prolonged with Envarsus XR compared to Advagraf (325 vs. 125 minutes, p<0.001).
[ADDRESS_516306] to compare the efficacy and safety of IR tacrolimus with conversion to Envarsus XR in kidney transplant recipi[INVESTIGATOR_840]. The primary efficacy endpoint was a composite of death, graft failure, biopsy -proven acute rejection (BPAR), or loss to follow -up over a 12 
month period. Tacrolimus TDD was decreased by 30% in patients converted to E nvarsus XR. There was 
a significant decrease in TDD with conversion to Envarsus XR despi[INVESTIGATOR_409403]. The efficacy endpoint was similar between groups (2.5 vs. 2.5%, p>0.999). Additionally, there were no differences between individual components of the composite endpoint. A subsequent prospective, double- blind, 
double- dummy, multicenter, phase III comparison of IR tacolimus and de novo Envarsus XR was 
conducted to demonstrate non- inferiority at 24- months follow -up. Treatment failure defined as death, 
transplant failure, BPAR, or loss to follow -up was similar between the two drugs (Envarsus XR 23.1%, IR 
tacrolimus 27.3%) and well below the 10% non- inferiority margin. There was no significant difference in 
safety outcomes, including changes in estimated glomerular filtration rate (eGFR) and serum creatinine (Scr) was similar between groups. Certain subgroup populations (African- American race, age > 65, 
female gender) demonstrated trends towards significant efficacy benefit with Envarsus XR, however these groups were too small reach statistical significance.
16 
 A phase IIIb prospective study compared continuation of IR tacrolimus to Envarsus XR conversion in patients on IR tacrolimus with significant tremor. Improvement in tremor with conversion to Envarsus XR was documented by [CONTACT_409432] -reported quality -of-life (78.9% 
reported improvement with conversion).
19  
2.2.3  Dose Rationale (if applicable)  
Dosing will be converted on an individual basis. Because all patients will be initiated on IR tacrolimus via the sublingual or enteral route, conversion will be dependent on several factors: tacrolimus TDD, tacrolimus trough level, and patient clinical status (i.e. infection, rejection, acute kidney injury, etc.). Envarsus XR 
conversion dose will be decided upon by [CONTACT_409433], who are also members of the study team.  
2.3 Rationale  
Tacrolimus is the primary immunosuppressant medication administered following lung transplant. Despi[INVESTIGATOR_160942], tacrolimus is limited by [CONTACT_409434] (PK), variabilit y in systemic 
exposure, difficulties with therapeutic drug monitoring, concentration- related neurologic side effects, and 
poor patient adherence. Envarsus XR is a once- daily, extended- release formulation of tacrolimus that 
utilizes MeltDose technology to optimize the pharmacokinetics of tacrolimus. Phase II studies in kidney transplant recipi[INVESTIGATOR_409402] -to-trough levels for Envarsus XR as 
compared to IR tacrolimus. Additionally, bioavailability was improved to 30% from 17% with a stronger correlation between trough concentration (C
0) and AUC.  
 Recent data in lung transplant recipi[INVESTIGATOR_409410]- in-therapeutic range for tacrolimus 
by 10% within the first year post -transplant reduced the burden of ACR by 54%.
9 Similar data was rece ntly 
published in heart transplant recipi[INVESTIGATOR_409411] C
0 levels.10 Taken together, these data highlight the clinical 
Study number:  i19-[ZIP_CODE]   Page 7 
Version: December 10, 2021    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_409435]. Envarsus XR may improve 
immunologic outcomes in lung transplant recipi[INVESTIGATOR_409412] a stable pharmacokinetic profile and 
minimizing variability.  
2.4 Potential Risks & Benefits 
2.4.[ADDRESS_516307] similarly been 
equivocal or typi[INVESTIGATOR_409413].
19 This study involves minimal to no risk to 
individual patients as it is a retrospective review of medical records and will involve collection and storage of de- identified patient data only.  
 
 
2.4.2  Known Potential Benefits 
The potential benefits of this study include improved adherence and convenience of maintenance immunosuppressive therapy, reduction in neurologic adverse effects (e.g. tremor) as demonstrated in the STRATO trial,
[ADDRESS_516308] benefit to the historical control cohort.  
3 Objectives and Purpose  
3.1 Primary Objective  
The primary objective will be to assess the feasibility of early conversion to Envarsus XR at 1- year follow -
up. 
3.2 Secondary Objectives (if applicable)  
Secondary objectives will be to assess immunologic outcomes that may be impacted by [CONTACT_409436]- related side effects.  
4 Study Design and Endpoints  
4.1 Description of Study Design  
This study will be a prospective, open- label, non- randomized, parallel arm, single -center trial comparing 
new lung transplant recipi[INVESTIGATOR_409414] a historical cohort of patients who received IR tacrolimus.  
4.2 Study Endpoints  
4.2.1  Primary Study Endpoints 
The primary endpoint will be percentage of patients remaining on Envarsus XR at 1- year follow -up. 
4.2.2  Secondary Study Endpoints  
Secondary endpoints will include freedom from ACR at 1- year follow -up, ACR burden at 1- year follow -up 
as assessed by [CONTACT_409437] (CRSS) ,20 treated epi[INVESTIGATOR_409415], the 
incidence of chronic lung allograft dysfunction (CLAD) at 1- year, incidence of de novo DSA in the first 
postoperative year, change in estimated glomerular filtration rate (eGFR) over the first post -operative 
year, and 1- year survival.  
Study number:  i19-[ZIP_CODE]   Page 8 
Version: December 10, [ADDRESS_516309] meet all of the following criteria:  
Prospective arm :  
1. Age ≥ [ADDRESS_516310] -transplant  
4. Able and willing to provide informed consent  
Historical control :  
1. Age ≥ 18 years  
2. Received a lung or heart -lung transplant at NYU Langone Health  
3. Completed one year from transplant on IR tacrolimus 
5.2 Exclusion Criteria  
An individual who meets any of the following criteria will be excluded from participation in this study:  
Prospective arm :  
1. Contraindication to tacrolimus due to allergic or adverse reactions  
2. Pregnant or nursing women 
Historical control :  
1. Contraindication to tacrolimus due to allergic or adverse reactions (not including chronic kidney 
disease)  
5.[ADDRESS_516311] of care for evaluation for a lung transplant.  
 Written informed consent for enrollment in the study will occur once the patient has been listed for lung transplantation in a private patient clinic room. Timing of consent for enrollment in relation to 
transplant date will vary between patients as acuity of disease is variable and waiting time to 
transplant is unpredictable.  
 The target sample size for the Prospective Cohort is 40 patients with early conversion to Envarsus XR. 
5.4.1  Use of DataCore/Epic Information for R ecruitment 
Purposes 
This study will utilize EPIC to identify subjects.  
 Any recruitment information sent by [CONTACT_409438].  
 
Study number:  i19-[ZIP_CODE]   Page 9 
Version: December 10, 2021    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_409439], as they will be under their care as candidates 
and/or waitlist registrants for lung transplant. The study team will conduct an in person consultation with 
the patients to explain the study as well as discuss the risks, benefits, and alternatives  
 
Approved recruitment language will be used to communicate the reason they are being contact[CONTACT_409440]. Should the 
potential subjects agree, the study team will provide the subjects with information regarding the next steps for participation.  
 If a subject requests information regarding opting out of further recruitment for all research, subj ects 
will be directed to contact [CONTACT_79161]- contact -[EMAIL_2365] or 1- [PHONE_2698].  
5.[ADDRESS_516312]. An investigator 
may terminate participation in the study if:  
• Any clinical adverse event (AE), laboratory abnormality, or other medical condition or situation 
occurs such that continued participation in the study would not be in the best interest of the 
participant  
• The participant meets an exclusion criterion (either newly developed or not previously recognized) that precludes further study participation  
5.7.[ADDRESS_516313].  
5.8 Premature Termination or Suspension of Study  
This study  may be temporarily suspended or prematurely terminated if there is sufficient reasonable 
cause. Written notification, documenting the reason for study suspension or termination, will be provided 
by [CONTACT_87077], funding agency, and regulatory authorities. If the study is prematurely terminated or suspended, the PI [INVESTIGATOR_118627](s) for the termination or suspension.  
 
Circumstances that may warrant termination or suspension include, but are not limited to:  
• Determination of unexpected, significant, or unacceptable risk to participants  
• Demonstration of efficacy that would warrant stoppi[INVESTIGATOR_007]  
• Insufficient compliance to protocol requirements  
• Data that are not sufficiently complete and/or evaluable 
• Determination of futility  
 Study may resume once concerns about safety, protocol compliance, data quality are addressed and satisfy the sponsor, IRB and/or FDA.  
Study number:  i19-[ZIP_CODE]   Page 10 
Version: December 10, 2021    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_4530]  6 Study Agent  (Study drug, device, biologic, vaccine  etc.) and/or 
Procedural Interve ntion  
6.1 Study Agent(s) and Control Description  
Envarsus XR is available in tablet form. It is available in 0.75, 1, and 4 mg tablets.  
 In accordance with 21 CFR 312.2(b)(1):  
 
(i) The investigation is not intended to be reported to FDA as a well -controlled study in support of 
a new indication for use nor intended to be used to support any other significant change in the labeling for the drug;  
  
(ii) the investigation is not intended to support a significant change in the advertising for the product;  
 
 
(iii) The investigation does not involve a route of administration or dosage level or use in a patient population or other factor that significantly increases the risks (or decreases the acceptability of the risks) associated with the use of the drug product;  
 
(iv) The investigation is conducted in compliance with the requirements for institutional review set forth in part 56 and with the requirements for informed consent set forth in part 50; and  
 The investigation is conducted in compliance with the requirements of 312.7.  
 
6.1.[ADDRESS_516314] protocols.  
 
6.1.2  Formulation, Appearance, Packaging, and 
Labeling  
This is an open label study and the drug will appear as it provided directly from the manufacturer, Veloxis Pharmaceuticals, Inc . The tablets are oval, white to off -white uncoated extended- release tablets, 
debossed with “TCS” on one side and “0.75”, “1”, or “4” on the other side depending on the strength of the tablet.  The drug will be packed in the standard manufacturer’s packing and all standard package inserts 
will be retained.  This product is commercially available and is FDA- approved for use in kidney transplant 
recipi[INVESTIGATOR_409416].  
6.1.[ADDRESS_516315] Storage and Stability  
Store at 25 °C (77 °F); excursions permitted to 15 °C to 30 °C (59 °F to 86 °F) . 
6.1.[ADDRESS_516316]. The dose can include any combination of the 0.75, 1 and 4  
mg tablets. The tablet should be swallowed whole, and should not be split, chewed or crushed.  
Study number:  i19-[ZIP_CODE]   Page 11 
Version: December 10, [ADDRESS_516317] based on the patients current dose of sublingual or enteral IR tacrolimus and the corresponding C
0 level.  
6.1.8  Dose Adjustments/Modifications/Delays 
Dose adjustments will be made based on corresponding C [ADDRESS_516318] be reported to the PI [INVESTIGATOR_97318]. The PI [INVESTIGATOR_5768]- investigator will review drug 
accountability during routine monitoring visits.  
 The accountability records will contain complete records of receipt, storage, dispensation and return for all used and unused tablets of Envarsus XR. Documentation will include batch numbers, expi[INVESTIGATOR_31637], and quantities received/dispensed/returned/destroyed. The accountability records and the study drug must be reconciled and discrepancies between the amount received, dispensed and returned/destroyed 
drug must be accounted for. This is applicable for unused, used and partially used and deliberately or 
accidentally damaged tablets of study drug.  
 Unused or damaged study drug must be kept at the Investigational Pharmacy until study closure and then returned to Veloxis Pharmaceuticals unless otherwise agreed upon with Veloxis Pharmaceuticals. Used 
study drug will be destroyed by [CONTACT_409441] [INVESTIGATOR_409417].  
6.2.[ADDRESS_516319] -operative care to ensure therapeutic 
levels are maintained.  
7 Study Procedures  and Schedule  
7.1 Study Procedures/Evaluations  
7.1.[ADDRESS_516320]- of-care procedures and evaluations 
Study number:  i19-[ZIP_CODE]   Page 12 
Version: December 10, [ADDRESS_516321]- of-care including: the 
transplant procedure itself and requisite intra- operative procedures and hemodynamic monitoring, 
post-operative ICU -level care, inpatient hospi[INVESTIGATOR_409418], outpatient post -operative care including, 
standard induction and maintenance immunosuppression, and standard post -transplant anti -infectious 
prophylaxis (anti -fungal, anti -pneumocystis, and anti -CMV proph ylaxis). In accordance, clinical data 
resulting from these procedures will be collected at the following timepoints:  
 
• Pathological rejection grading from transbronchial biopsies performed at 1, 3, 6, and [ADDRESS_516322] -transplant  
• Any requirement for augmented immunosuppression for treatment of documented or 
presumed rejection  
• Forced expi[INVESTIGATOR_3741] 1 second (FEV 1) measurements monthly  
• De novo DSA as assessed by [CONTACT_409442] 1, 3, 6, 9, and [ADDRESS_516323] -transplant  
7.2 Labora tory Procedures/Evaluations  
7.2.[ADDRESS_516324] of care for lung transplant recipi[INVESTIGATOR_840]:  
 
• Hematology: white  blood cells (WBC)   collected weekly for the first 3 
months and monthly for months 4- 12 
• Biochemistry: potassium and creatinine collected weekly for the first 3 
months and monthly for months 4- 12 
• Tacrolimus:  C0 levels will be obtained at all routine post -transplant follow -
up visits and more frequently as needed for sub- or supra- therapeutic levels 
collected weekly for the first [ADDRESS_516325] of care 
for patients undergoing a lung transplant.  
7.3.1  Precautionary Medications, Treatments, and 
Procedures  
Treatment with potent CYP3A4 inducers (e.g. rifampin, St. John’s Wort, efavirenz, carbamazepi[INVESTIGATOR_050], 
phenytoin, phenobarbital, etc.) or inhibitors (ritonavir, cobicistat, darunavir, lopi[INVESTIGATOR_054], atazanavir, etc.) 
requires special dosing considerations and potentially more frequent monitoring of tacrolimus C 0 levels. 
Study number:  i19-[ZIP_CODE]   Page 13 
Version: December 10, [ADDRESS_516326], who would also be a study team member.  
 
8 Assessment of S afety  
8.1 Specification of Safety Parameters  
8.1.1  Definition of Adverse Events (AE)  
An adverse event  (AE) is any symptom, sign, illness or experience that develops or worsens in severity 
during the course of the study.  Intercurrent illnesses or injuries should be regarded as adverse events.  
Abnormal results of diagnostic procedures are considered to be adverse events if the abnormality:  
• results in study withdrawal  
• is associated with a serious adverse event  
• is associated with clinical signs or symptoms  
• leads to additional treatment or to further diagnostic tests 
• is considered by [CONTACT_1372] 
8.1.2  Definition  of Serious Adverse Events (SAE)  
 
Serious Adverse Event  
Adverse events are classified as serious or non- serious.  A serious adverse event  is any AE that is:  
• fatal 
• life-threatening  
• requires or prolongs hospi[INVESTIGATOR_4408]  
• results in persistent or significant disability or incapacity  
• a congenital anomaly or birth defect  
• an important medical event  
 Important medical events are those that may not be immediately life threatening, but are clearly of major clinical significance. They may jeopardize the subject, and may require intervention to prevent one of the other serious outcomes noted above. For example, drug overdose or abuse, a seizure that did not result in in-patient hospi[INVESTIGATOR_059], or intensive treatment of bronchospasm in an emergency department would 
typi[INVESTIGATOR_15355].  
 All adverse events that do not meet any of the criteria for serious should be regarded as non -serious 
adverse events.  
Study number:  i19-[ZIP_CODE]   Page 14 
Version: December 10, 2021    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_4530]  8.1.3  Definition of Unanticipated Problems (UP)  
 
Unanticipated Problems Involving Risk to Subjects or Others  
Any incident, experience, or outcome that meets all  of  the following criteria:  
• Unexpected in nature, severity, or frequency   (i.e. not described in study -related documents such 
as the IRB -approved protocol or consent form, the investigators brochure, etc)  
• Related or possibly related to participation in the research ( i.e. possibly related means there is a 
reasonable possibility that the incident experience, or outcome may have been caused by [CONTACT_3459])  
• Suggests that the research places subjects or others at greater risk of harm  (
 including physical, 
psychological, economic, or social harm).  
8.2 Classification of an Adverse Event  
8.2.1  Severity of Event  
For AEs not included in the protocol defined grading system, the following guidelines will be used to describe severity.  
 
• Mild – Events require minimal or no treatment and do not interfere with the participant’s daily 
activities.  
• Moderate  – Events result in a low level of inconvenience or concern with the therapeutic 
measures. Moderate events may cause some interference with func tioning.  
• Severe  – Events interrupt a participant’s usual daily activity and may require systemic drug 
therapy or other treatment. Severe events are usually potentially life- threatening or incapacitating.  
8.2.2  Relationship to Study Agent  
The clinician’s assessment of an AE's relationship to study drug is part of the documentation process, but it is not a factor in determining what is or is not reported in the study. If there is any doubt as to whether a clinical observation is an AE, the event should be reported. All AEs must have their relationship to study agent assessed. In a clinical trial, the study product must always be suspect. To help assess, the following guidelines are used.  
 
• Related – The AE is known to occur with the study agent, there is a reasonable possibility that the 
study agent caused the AE, or there is a temporal relationship between the study agent and event. Reasonable possibility means that there is evidence to suggest a causal relationship between the 
study agent and the AE.  
• Not Rel ated – There is not a reasonable possibility that the administration of the study agent 
caused the event, there is no temporal relationship between the study agent and event onset, or 
an alternate etiology has been established.  
 For all collected AEs, the clinician who examines and evaluates the participant will determine the AE’s causality based on temporal relationship and his/her clinical judgment. The degree of certainty about causality will be graded using the categories below.  
• Definitely Related  – There is clear evidence to suggest a causal relationship, and other possible 
contributing factors can be ruled out. The clinical event, including an abnormal laboratory test result, occurs in a plausible time relationship to drug administration and cannot be explained by [CONTACT_9153]. The response to withdrawal of the drug (dechallenge) should be clinically plausible. The event must be pharmacologically or 
phenomenologically definitive, with use of a satisfactory rechallenge procedure if necessary.  
• Probably Related  – There is evidence to suggest a causal relationship, and the influence of other 
factors is unlikely. The clinical event, including an abnormal laboratory test result, occurs within a reasonable time after administration of the drug, is unlikely to be attributed to concurrent disease 
Study number:  i19-[ZIP_CODE]   Page 15 
Version: December 10, 2021    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_409443], and follows a clinically reasonable response on withdrawal 
(dechallenge). Rechallenge information is not required to fulfill this definition.  
• Possibly Related  – There is some evidence to suggest a causal relationship (e.g., the event 
occurred within a reasonable time after administration of the trial medication). However, other factors may have contributed to the event (e.g., the participant’s clinical condition, other concomitant events). Although an AE may rate only as “possibly related” soon after discovery, it 
can be flagged as requiring more information and later be upgraded to “probably related” or 
“definitely related,” as appropriate.  
• Unlikely to be relat ed – A clinical event, including an abnormal laboratory test result, whose 
temporal relationship to drug administration makes a causal relationship improbable (e.g., the event did not occur within a reasonable time after administration of the trial medicat ion) and in 
which other drugs or chemicals or underlying disease provides plausible explanations (e.g., the participant’s clinical condition, other concomitant treatments).  
• Not Related  – The AE is completely independent of study drug administration, and/or  evidence 
exists that the event is definitely related to another etiology. There must be an alternative, definitive etiology documented by [CONTACT_15370].  
8.2.3  Expectedness 
The Principal Investigator [INVESTIGATOR_118631]. An AE will be considered unexpected if the nature, severity, or frequency of the event is not consistent with the risk information previously described for the study agent.  
8.3 Time Period and Frequency for Event Assessment and Follow -Up 
The occurrence of an AE or SAE may come to the attention of study personnel during study visits and interviews of a study participant presenting for medical care, or upon review by a study monitor. All AEs 
including local and systemic reactions not meeting the criteria for SAEs will be captured on the 
appropriate RF. Information to be collected includes event description, time of onset, clinician’s assessment of severity, relationship to study product (assessed only by [CONTACT_8703] a diagnosis), and time of resolution/stabilization of the event. All AEs occurring while on 
study must be documented appropriately regardless of relationship. All AEs will be followed to adequate resolution.  
 Any medical condition that is present at the time that the participant is screened will be considered as baseline and not reported as an AE. However, if the study participant’s condition deteriorates at any time during the study, it will be recorded as an AE. UPs will be recorded in the data collection system throughout the study.  
 Changes in the severity of an AE will be documented to allow an assessment of the duration of the event at each level of severity to be performed. AEs characterized as intermittent require documentation of onset and duration  of each epi[INVESTIGATOR_1865].  
 The PI [INVESTIGATOR_46183] 7 (for non- serious AEs) or 30 days (for SAEs) after the last day of study participation. At 
each study visit, the investigator will inquire about the occurrence of AE/SAEs since the last visit. Events 
will be followed for outcome information until resolution or stabilization.   
 All unresolved adverse events should be followed by [CONTACT_1374], the subject is lost to follow -up, or the adverse event is otherwise explained.  At the last scheduled visit, the 
investigator should instruct each subject to report any subsequent event(s) that the subject, or the subject’s personal physician, believes  might reasonably be related to participation in this study.  The 
investigator should notify the study sponsor of any death or adverse event occurring at any time after a subject has discontinued or terminated study participation that may reasonably be rel ated to this study.  
The sponsor should also be notified if the investigator should become aware of the development of cancer or of a congenital anomaly in a subsequently conceived offspring of a subject that has participated 
in this study.  
Study number:  i19-[ZIP_CODE]   Page 16 
Version: December 10, 2021    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_4530]  8.4 Reporting Proc edures – Notifying the IRB  
8.4.1  Adverse Event Reporting 
All AEs will be recorded in AE CRFs by a member of the study team only if they are related to the study 
drug. AEs will be recorded within 3 business days of the study team being made aware of the AE. The relationship of the AE to the study drug will be noted by [CONTACT_978]. AEs that are deemed definitely related or probably related to the study drug will be reported to the IRB. within 3 days of their designation as such. AEs that are deemed unrelated or not likely related to the study drug will be recorded on CRFs 
as described above and will be reviewed at quarterly safety review meetings with the Safety Monitor, 
and at annual review by [CONTACT_1201].  
8.4.2  Serious Adverse Event Reporting  
All SAEs will be recorded in SAE CRFs by a member of the study team. SAEs will be recorded within 3 business days of the study team being made aware of the SAE. The relationship of the SAE to the study drug will be noted by [CONTACT_978]. SAEs that are both unexpected and deemed related to the s tudy 
drug will be reported to the IRB and the Safety Monitor within 24 hours of the PI [INVESTIGATOR_409419]. The Safety Monitor will determine the need for an emergency meeting between the Safety Monitor and the study team (see safety oversight below) or whether these can be reviewed at quarterly 
meetings. SAEs that are deemed unrelated or not likely related to the study drug will be recorded on 
CRFs, will be reported to IRB and Safety Monitor within 3 days of their designation as such and will be reviewed at quarterly safety meetings.  
8.4.3  Unanticipated Problem Reporting  
Incidents or events that meet the OHRP criteria for UPs require the creation and completion of an UP report form. It is the PI’s responsibility to report UPs to their IRB and notify the Safety Monitor. The UP report will include the following information:  
 
• Protocol identifying information: protocol title and number, PI’s name, and the IRB project number;  
• A detailed description of the event, incident, experience, or outcome;  
• An explanation of the basis for determining that the event, incident, experience, or outcome represents an UP;  
• A description of any changes to the protocol or other corrective actions that have been taken or are proposed in response to the UP.  
 
To satisfy the requirement for prompt reporting, UPs will be reported using the following timeline:  
 
• UPs that are SAEs  will be reported to the IRB within  3 days  the investigator  becoming aware 
of the event.  
• Any other  UP will be reported to the IRB within  [ADDRESS_516327] of care transplant medications has occurred.  
8.5 Reporting Procedures – Notifying the Study Sponsor  
 
Study number:  i19-[ZIP_CODE]   Page 17 
Version: December 10, 2021    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_409444] a SAE Form within the following timelines:  
 
• All deaths and immediately life- threatening events, whether related or unrelated, will be recorded 
on the SAE Form and submitted to the study sponsor within [ADDRESS_516328] information.  
• Other SAEs regardless of relationship will be submitted to the study sponsor within [ADDRESS_516329] -lung transplant, along with the off -label use of an approved FDA medication 
(Envarsus XR) for prevention of acute rejection following lung transplant and with the recommended dosing. Additionally, this trial will not be looking for a new indication or use of Envarsus XR.  
 Safety oversight will be under the direction of the PI [INVESTIGATOR_1238] a Safety Monitor with expertise in 
transplantation (Claudia Gidea, MD – Transplant Cardiology). This individual will be involved as a 
consultant but not as an investigator of the trial and will provide an independent evaluation of each 
one of the SAE related to the treatment with Envarsus XR. Furthermore, the PI [INVESTIGATOR_409420]. The Safety Monitor will review de- identified data only.  
[ADDRESS_516330] of 
the trial is in compliance with the currently approved protocol/amendment(s), with GCP, and with 
applicable regulatory requirement(s).  
10 Statistical Considerations  
10.1 Statistical and Analytical Plans (SAP)  
No formal SAP is required as the study will employ only a single prospective arm with comparison to a historical control.  
Study number:  i19-[ZIP_CODE]   Page 18 
Version: December 10, [ADDRESS_516331] -lung transplant will be reduced by [CONTACT_409445]. Additionally, we hypothesize 
that key related immunologic outcomes, de novo DSA and CLAD, may be reduced due to less frequent 
rejection.  
10.3 Analysis Datasets  
All subjects will be entered into a database containing de- identified information. All patients who take one 
dose of the study drug will be included in the safety analyses (intention- to-treat). However, only patients 
completing the full first year post -lung transplant will be included in the efficacy analysis (per -protocol 
analysis).  
10.[ADDRESS_516332]. Continuous data will 
be presented as median (interquartile range) and compared using Mann- Whitney U test. A two -tailed P 
value of < 0.05 will be considered as significant for inferential tests.  
10.4.2  Analysis of the Primary Efficacy Endpoint(s)  
The primary endpoint, percentage of patients remaining on Envarsus XR at 1- year, will be measured as a 
single endpoint on a nominal scale. It will be analyzed using descriptive statistics.  
10.4.3  Analysis of the Secondary Endpoint(s)  
 
1. Freedom from ACR will be compared using Kaplan- Meier survival analysis and the log- rank test.  
2. Composite rejection standardized score at 1 year follow -up will be presented as median (IQR) 
and will be compared using the Mann- Whitney U test  
3. Treated epi[INVESTIGATOR_409421] -square 
test 
4. Incidence of CLAD at 1 year will be presented as odds ratio with 95% confidence intervals and compared between groups using logistic regression.  
5. Incidence of de novo DSA at 1 year will be presented as odds ratio with 95% confidence intervals 
and compared using between groups using logistic regression.  
6. Mortality a [ADDRESS_516333] patient inquiries regarding medication 
adherence.  
Study number:  i19-[ZIP_CODE]   Page 19 
Version: December 10, 2021    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_4530]  10.4.6  Baseline Descriptive Statistics  
Baseline statistics including but not limited to age, gender, etiology of lung disease, type of lun g 
transplant, lung allocation score, details of the requirement for mechanical ventilation or extracorporeal 
membrane oxygenation, and ischemic time of the organ will be collected for each group. These data will be compared using chi -square tests to assess  for baseline imbalances.  
10.4.7  Planned Interim Analysis  
No interim analysis is planned.  
[IP_ADDRESS]  Safety Review  
Any patient death will result in halting of any further enrollment in the study and an assessment of 
whether the death was related to Envarsus XR exposure or complications thereof. Even in the event of a 
patient death, currently enrolled patients who are actively being treated with Envarsus XR and tolerating therapy will continue to receive therapy so as not to put them at risk for rejection as a consequence of converting therapy. If the patient death is deemed related to Envarsus XR, enrolled patients receiving Envarsus XR will be switched to an alternative therapy including, but not limited to: IR tacrolimus, cyclosporine, sirolimus, everolimus, mycophenolate, belatacept, or some combination thereof.  
[IP_ADDRESS]  Efficacy Review  
There will be no interim analyses performed due to the small sample size and anticipated short duration of enrollment for the study.  
10.5 Sample Size  
We plan to prospectively enroll 40 patients into the Envarsus XR arm to provide a 2:[ADDRESS_516334] lung transplant while maintained on IR tacrolimus. The 
2:1 sample size was chosen as the purpose of the study is to gain experience with Envarsus XR in lung transplant recipi[INVESTIGATOR_409422]. As this is a pi[INVESTIGATOR_799], there will be no power calculations.   
 
11 Source Documents and Access to Source Data/Documents  
Source data is all information, original records of clinical findings, observations, or other activities in a clinical trial necessary for the reconstruction and evaluation of the trial.  Source data are contained in source documents. Examples of these original documents, and data records include: hospi[INVESTIGATOR_1097], clinical and office charts, laboratory notes, memoranda, subjects’ diaries or evaluation checklists, pharmacy dispensing records, recorded data from automated instruments, copi[INVESTIGATOR_10379], microfiches, photographic negatives, microfilm 
or magnetic media, x -rays, subject files, and records kept at the pharmacy, at the laboratories, and at 
medico- technical departments involved in the clinical trial.  It is acceptable to use CRFs as source 
documents. If this is the case, it should be stated in this section what data will be collected on CRFs and 
what data will be collected from other sources.  
 
The study case report form (CRF) is the primary data collection instrument for the study.  All data 
requeste d on the CRF must be recorded. All missing data must be explained. If a space on the CRF is left 
blank because the procedure was not done or the question was not asked, write “N/D”. If the item is not applicable t o the individual case, write “N/A”.  All entries will be stored in REDCap.  
 Access to study records will be limited to IRB -approved members of the study team. The investigator will 
permit study -related monitoring, audits, and inspections by [CONTACT_1201]/EC , the sponsor, government 
regulatory bodies, and University compliance and quality assurance groups of all study related 
Study number:  i19-[ZIP_CODE]   Page 20 
Version: December 10, 2021    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_409446] (e.g. source documents, regulatory documents, data collection instruments, study data etc.).  
The investigator will ensure the capability for inspections of applicable study -related facilities (e.g. 
pharmacy, diagnostic laboratory, etc.).  
 Participation as an investigator in this study implies acceptance of potential inspection by [CONTACT_17256].  
12 Quality Assurance and Quality Control  
QC procedures will be implemented beginning with the data entry system and data QC checks that will be run on the database will be generated. Any missing data or data anomalies will be communicated to the site(s) for clarification/resolution.  
 Following written SOPs, the monitors will verify that the clinical trial is conducted and data are generated, documented (recorded), and reported in compliance with the protocol, GCP, and the applicable regulatory requirements (e.g., Good Laboratory Practices (GLP), Good Manufacturing Practices (GMP)).  
 The investigational site will provide direct access to all trial related sites, source data/documents, and 
reports for the purpose of monitoring and auditing by [CONTACT_456], and inspection by [CONTACT_90471].  
13 Ethics/Protection of Human Subjects  
13.[ADDRESS_516335]  
The investigator will ensure that this study is conducted in full conformity with Regulations for the Protection of Human Subjects of Research codified in 45 CFR Part 46, 21 CFR Part 50, 21 CFR Part 56, and/or the ICH E6.  
13.[ADDRESS_516336]  
The protocol, informed consent form(s), recruitment materials, and all participant materials will be 
submitted to the IRB for review and approval. Approval of both the protocol and the consent form must be 
obtained before any participant is enrolled. Any amendment to the protocol will require review and approval by [CONTACT_3484]. All changes to the consent form will be IRB approved; a determination will be made regarding whether previously consented participants need to be re- consented.  
13.3 Informed Consent Process  
13.3.1  Consent/Assent and Other Informational 
Documents Provided to Participants (Envarsus XR Prospective Cohort)  
Consent forms describing in detail the study agent, study procedures, and risks are given to the participant and written documentation of informed consent is required prior to starting intervention/administering study product. The informed consent document to be used is submitted with 
this protocol.  
13.3.2  Consent Procedures and Documentation  
Informed consent is a process that is initiated prior to the individual’s agreeing to participate in the study and continues throughout the individual’s study participation. Extensive discussion of risks and possible benefits of participation will be provided to the participants and their families. Consent forms will be IRB -
approved and the participant will be asked to read and review the document. The investigator will explain 
the research study to the participant and answer any questions that may arise. All participants will receive 
a verbal explanation in terms suited to their comprehension of the purposes, procedures, and potenti al 
risks of the study and of their rights as research participants. Participants will have the opportunity to carefully review the written consent form and ask questions prior to signing. The participants should have 
Study number:  i19-[ZIP_CODE]   Page 21 
Version: December 10, [ADDRESS_516337]’s research record. The 
consent process, including the name [CONTACT_21811], will be thoroughly documented in 
the subject’s research record. Any alteration to the standard consent process (e.g. use of a translator, consent document presented orally, etc.) and the justification for such alteration will likewise be documented.  
13.[ADDRESS_516338] of 1996 (HIPAA).  Those regulations require a 
signed subject authorization informing the subject of the following:  
• What protected health information (PHI) will be collected from subjects in this study  
• Who will have access to that information and why 
• Who will use or disclose that information  
• The rights of a research subject to revoke their authorization for use of their PHI.  
 
In the event that a subject revokes authorization to collect or use PHI, the investigator, by [CONTACT_5151], retains the ability to use all information collected prior to the revocation of subject authorization.  For 
subjects that have revoked authorization to collect or use PHI, attempts should be made to obtain 
permission to collect at least vital status (i.e. that the subject is alive) at the end of their scheduled study period.  
 Participant confidentiality is str ictly held in trust by [CONTACT_3486], their staff, and the 
sponsor(s) and their agents. Therefore, the study protocol, documentation, data, and all other information 
generated will be held in strict confidence. No information concerning the study or the data will be 
released to any unauthorized third party without prior written approval of the sponsor.  
 The study monitor, other authorized representatives of the sponsor, representatives of the IRB or pharmaceutical company supplying study product may inspect all documents and records required to be maintained by [CONTACT_093], including but not limited to, medical records (office, clinic, or hospi[INVESTIGATOR_307]) and 
pharmacy records for the participants in this study. The clinical study site will permit access to such 
records.  
 The study participant’s contact [CONTACT_409447]. At the end of the study, all records will continue to be kept in a secure location for as long a period 
as dictated by [CONTACT_46202].  
 
Study participant research data, which is for purposes of statistical analysis and scientific reporting, will be transmitted to and stored at NYU Langone Medical Center. This will not include the partic ipant’s 
contact [CONTACT_1290]. Rather, individual participants and their research data will be identified by a unique study identification number. The study data entry and study management systems used by 
[CONTACT_409448]. At 
the end of the study, all study databases will be de- identified and archived at the NYU Langone Medical 
Center.  
Study number:  i19-[ZIP_CODE]   Page 22 
Version: December 10, [ADDRESS_516339] completed the study visits , Laboratory Evaluation windows will open up to +/ -[ADDRESS_516340] s the status of 
these subjects month- to-month as there is variability in the scheduling of labs due to many clinical factors . 
This will also more closely align with the window, +/ - 28 days, for the bronchoscopi[INVESTIGATOR_409423] y visits as well.  
 The window for the Year 1 visits (Study Visit Week 52) will also open to +/ - [ADDRESS_516341] -transplant.  
 De-identified clinical data (including AEs, concomitant medications, and expected adverse reactions 
data) and clinical laboratory data will be assimilated in the study subject binders. Clinical data will be entered directly to electronic CRFs in REDCap.  
  
14.2 Study Records Retention  
Study documents will be retained for the longer of 3 years after close- out, 5 years after final 
reporting/publication , or 2 years after the investigation is discontinued. No records will be destroyed 
without the written consent of the sponsor, if applicable. It is the responsibility of the sponsor to inform the investigator when these documents no longer need to be retained.  
14.3 Protocol Deviations  
A protocol deviation is any noncompliance with the clinical trial protocol, GCP, or Manual of Procedures 
(MOP) requirements. The noncompliance may be either on the part of the participant, the investigator, or 
the study site staff. As a result of deviations, corrective actions are to be developed by [CONTACT_3483].  
 These practices are consistent with ICH E6:  
• 4.5 Compliance with Protocol, sections 4.5.1, 4.5.2, and 4.5.3  
• 5.1 Quality Assurance and Quality Control, section 5.1.1  
• 5.20 Noncompliance, sections 5.20.1, and 5.20.2.  
 It is the responsibility of the site PI/study staff to use continuous vigilance to identify and report deviations 
within [ADDRESS_516342] be addressed in study source documents, reported to the PI [INVESTIGATOR_82141].  During the course of routine follow -up, certain adjustments from routine clinical, laboratory, and 
bronchoscopy schedules are deemed necessary per the clinical judgement of the treating transplant 
Study number:  i19-[ZIP_CODE]   Page 23 
Version: December 10, [ADDRESS_516343] be reported to the local IRB per their guidelines. The site PI/study staff is responsible for knowing and adhering to their IRB requirements. Further details about the handling of protocol deviations will be included in the MOP.  
14.4 Publication and Data Sharing Policy  
This study will comply with the NIH Public Access Policy, which ensures that the public has access to the published results of NIH funded research. It requires  scientists to submit final peer -reviewed journal 
manuscripts that arise from NIH funds to the digital archive PubMed Central upon acceptance for publication.  
 The International Committee of Medical Journal Editors (ICMJE) member journals have adopted a cl inical 
trials registration policy as a condition for publication. The ICMJE defines a clinical trial as any research project that prospectively assigns human subjects to intervention or concurrent comparison or control 
groups to study the cause- and-effect relationship between a medical intervention and a health outcome. 
Medical interventions include drugs, surgical procedures, devices, behavioral treatments, process -of-care 
changes, and the like. Health outcomes include any biomedical or health- related meas ures obtained in 
patients or participants, including pharmacokinetic measures and adverse events. The ICMJE policy, and 
the Section [ADDRESS_516344] of 2007, requires that all clinical 
trials be registered in a public trials registry such as ClinicalTrials.gov, which is sponsored by [CONTACT_118702]. Other biomedical journals are considering adopting similar policies. For interventional clinical trials performed under NIH IC grants and cooperative agreements, it is the grantee’s responsibility to register the trial in an acceptable registry, so the research results may be considered for publication in ICMJE member journals. The ICMJE does not review specific studies to determine whether registration is necessary; instead, the committee recommends that researchers who have questions about the need to 
register err on the side of registration or consult the editorial office of the journal in which they wish to 
publish.  
 FDAAA mandates that a "responsible party" (i.e., the sponsor or designated principal investigator) register and report results of certain "applicable clinical trials":  
 
• Trials of Drugs and Biologics: Controlled, clinical investigations, other than Phase I investigations of a product subject to FDA regulation;  
• Trials of Devices: Controlled trials with health outcomes of a product subject to FDA regulation (other than small feasibility studies) and pediatric postmarket surveillance studies.  
• NIH grantees must take specific steps to ensure compliance with NIH implementation of FDAAA.  
[ADDRESS_516345] quarterly 
Study number:  i19-[ZIP_CODE]   Page 24 
Version: December 10, [ADDRESS_516346] that is appropriate to their participation in the trial. The study leadership in conjunction with the <specify NIH IC> has established policies and procedures for all study group members to disclose all conflicts of interest and will establish a mechanism for the management of all reported dualities of interest.   
 Any investigator who has a conflict of interest with this study (patent ownership, royalties, or financial gain greater than the minimum allowable by [CONTACT_1385], etc.) must have the conflict reviewed by [CONTACT_33913] (CIMU)  with a Committee- sanctioned conflict management 
plan that has been reviewed and approved by [CONTACT_28833]. All NYULMC  investigators will follow the applicable conflict of interest policies . 
18 References  
 
1. Chambers DC, Cherikh WS, Goldfarb SB, et al. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty -fifth adult lung 
and heart -lung transplant report --2018; Focus theme: Multiorgan Transplantation. The Journal 
of Heart and Lung Transplantation 2018;37:1169- 83. 
2. DerHovanessian A, Wallace WD, Lynch JP, Belperio JA, Weigt SS. Chronic L ung Allograft 
Dysfunction: Evolving Concepts and Therapi[INVESTIGATOR_014]. Semin Respir Crit Care Med 2018;39:155- 71. 
3. Bando K, Paradis IL, Similo S, et al. Obliterative bronchiolitis after lung and heart -lung 
transplantation. An analysis of risk factors and management. The Journal of thoracic and cardiovascular surgery 1995;110:4- 13; discussion - 4. 
4. Burton CM, Iversen M, Carlsen J, et al. Acute cellular rejection is a risk factor for bronchiolitis obliterans syndrome independent of post -transplant baseline FEV1. The Journal of heart and 
lung transplantation : the official publication of the International Society for Heart Transplantation 2009;28:888- 93. 
5. Hachem RR, Khalifah AP, Chakinala MM, et al. The significance of a single epi[INVESTIGATOR_409424]. Transplantation 2005;80:1406- 13. 
6. Monchaud C, Marquet P. Pharmacokinetic optimization of immunosuppressive therapy in thoracic transplantation: part I. Clinical pharmacokinetics 2009;48:419- 62. 
7. Chiang CY, Schneider HG, Levvey B, Mitchell L, Snell GI. Tacrolimus Level Variability Is a Novel Measure Associated with Increased Acute Rejection in Lung Transplant (LTx) Recipi[INVESTIGATOR_840]. The Journal of Heart and Lung Transplantation 2013;32:S170.  
8. Gallagher HM, Sarwar G, Tse T, et al. Erratic tacrolimus exposure, assessed using the standard deviation of trough blood levels, predicts chronic lung allograft dysfunction and 
survival. The Journal of heart and lung transplantation : the official publication of the 
International Society for Heart  Transplantation 2015;34:1442- 8. 
9. Ensor CR, Iasella CJ, Harrigan KM, et al. Increasing tacrolimus time- in-therapeutic range is 
associated with superior one- year outcomes in lung transplant recipi[INVESTIGATOR_840]. 2018;18:1527- 33. 
10. Gueta I, Markovits N, Yarden- Bilavsky H, et al. High tacrolimus trough level variability is 
associated with rejections after heart transplant. 2018;18:2571- 8. 
11. Nigro V GA, Weinberg J. Improved Bioavailability of MELTDOSE Once- Daily Formulation of 
Tacrolimus (LCP -Tacro) with Controlled  Agglomeration Allows for Consistent Absorption over 
24 Hrs: A Scintigraphic and Pharmacokinetic Evaluation [abstract]. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant  Surgeons 2013;13.  
Study number:  i19-[ZIP_CODE]   Page 25 
Version: December 10, 2021    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_4530]  12. Staatz CE, Tett SEJCP. Clinical Pharmacokinetics of Once- Daily Tacrolimus in Solid- Organ 
Transplant Patients. 2015;54:993- 1025.  
13. Bunnapradist S, Ciechanowski K, West -Thielke P, et al. Conversion from twice- daily 
tacrolimus to once- daily extended release tacrolimus (LCPT): the phase III randomized MELT 
trial. American journal of transplantation : official journal of the American Society of 
Transplantation and the American Society of Transplant Surgeons 2013;13:760- 9. 
14. Gaber AO, Alloway RR, Bodziak K, Kaplan B, Bunnapradist S. Conversion From Twice- Daily 
Tacrolimus Capsules to Once- Daily Extended- Release Tacrolimus (LCPT): A Phase 2 Trial of 
Stable Renal Transplant Recipi[INVESTIGATOR_840]. 2013;96:191- 7. 
15. Tremblay S, Nigro V, Weinberg J,  Woodle ES, Alloway RR. A Steady -State Head -to-Head 
Pharmacokinetic Comparison of All FK -506 (Tacrolimus) Formulations (ASTCOFF): An Open-
Label, Prospective, Randomized, Two- Arm, Three- Period Crossover Study. 2017;17:432- 42. 
16. Rostaing L, Bunnapradist S,  Grinyo JM, et al. Novel Once- Daily Extended- Release Tacrolimus 
Versus Twice -Daily Tacrolimus in De Novo Kidney Transplant Recipi[INVESTIGATOR_840]: Two- Year Results 
of Phase 3, Double- Blind, Randomized Trial. American journal of kidney diseases : the official 
journal of the National Kidney Foundation 2016;67:648 -59. 
17. Sintes H, Sáez -Giménez B, Berastegui C, et al. Pharmacokinetic Study of Conversion 
Between 2 Formulations of Once- daily Extended- release Tacrolimus in Stable Lung 
Transplant Patients. 2018;102:e439- e46. 
18. Grinyo JM, Petruzzelli S. Once- daily LCP -Tacro MeltDose tacrolimus for the prophylaxis of 
organ rejection in kidney and liver transplantations. Expert review of clinical immunology 2014;10:1567- 79. 
19. Langone A, Steinberg SM, Gedaly R, et al. Switching STudy of Kidney TRansplant PAtients with Tremor to LCP -TacrO (STRATO): an open- label, multicenter, prospective phase 3b 
study. 2015;29:796- 805. 
20. Ensor CR, Rihtarchik LC, Morrell MR, et al. Rescue alemtuzumab for refractory acute cellular rejection and bronchiolitis obliterans syndrome after lung transplantation. 2017;31:e12899.  
 
 
Study number:  i19-[ZIP_CODE]   Page 26 
Version: December 10, 2021    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_4530]  19 Attachments  
These documents are relevant to the protocol, but they are not considered part of the protocol.  They are 
stored and modified separately. As such, modifications  to these documents do not require protocol 
amendments.  
Study number:  i19-[ZIP_CODE]   Page 27 
Version: December 10, 2021    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as authorized in writing by [CONTACT_4530]  20 Schedule of Events  
 
Activity  Screening Visit  
(POD 0 to30) SVD0*  SVW1 
(+/- 5 days)  SVW2 
(+/- 5 days)  SVW3 
(+/- 5 days)  SVW4 
(+/- 5 days)  SVW5 
(+/- 5 days)  
Study team procedures             
Consent  X       
Medical History  X       
Physical Exam  X       
Height  X       
Weight  X       
Vitals signs  X       
Review all recipi[INVESTIGATOR_346816]/exclusion 
criteria  X       
Study drug dispensation   X      
Participant study drug compliance 
check  and accountability       X  
Bronchoscopy with biopsy       X  
Spi[INVESTIGATOR_038] (FEV1)       X  
Donor -specific antibody       X  
Laboratory Evaluations         
Biochemistry   X X X X X 
Hematology    X X X X X 
Tacrolimus C 0   X X X X X 
SVD=study visit day; SVW=study visit week 
*Study visit day 0 = day of first drug dispensation and may occur on the same day as screening visit.  
*For SVW4 and SVW12: Bronchoscopi[INVESTIGATOR_409425] a window of +/- 14 days.   
  
Study number:  i19-[ZIP_CODE]   Page 28 
Version: December 10, 2021    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as authorized in writing by [CONTACT_409449]6 
(+/- 5 days)  SVW7 
(+/- 5 days)  SVW8 
(+/- 5 days)  SVW9 
(+/- 5 days)  SVW10 
(+/- 5 days)  SVW11 
(+/- 5 days)  SVW12 
(+/- 5 days)  
Study team procedures             
        
Participant study drug compliance 
check  and accountability    X    X 
Bronchoscopy with biopsy        X 
Spi[INVESTIGATOR_038] (FEV1)    X    X 
Donor -specific antibody        X 
Laboratory Evaluations         
Biochemistry X X X X X X X 
Hematology  X X X X X X X 
Tacrolimus C 0 X X X X X X X 
Activity  SVW16 
(+/- 5 days)  SVW20 
(+/- 5 days)  SVW24 
(+/- 5 days)  SVW28 
(+/- 5 days)  SVW32 
(+/- 5 days)  SVW36 
(+/- 5 days)  SVW40 
(+/- 5 days)  
Study team procedures               
        
Participant study drug compliance 
check  and accountability  X X X X X X X 
Bronchoscopy with biopsy    X     
Spi[INVESTIGATOR_038] (FEV1)  X X X X X X X 
Donor -specific antibody    X   X  
Laboratory Evaluations         
Biochemistry X X X X X X X 
Hematology  X X X X X X X 
Tacrolimus C 0 X X X X X X X 
 
Activity  SVW44 
(+/- 5 days)  SVW48 
(+/- 5 days)  SVW52 
(+/- 5 days)  
Study team procedures        
    
Participant study drug compliance check  
and accountability  X X X 
Study number:  i19-[ZIP_CODE]   Page 29 
Version: December 10, 2021    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as authorized in writing by [CONTACT_409450]    X 
Physical Exam    X 
Height    X 
Weight    X 
Vitals signs    X 
Bronchoscopy with biopsy    X 
Spi[INVESTIGATOR_038] (FEV1)  X X X 
Donor -specific antibody    X 
Laboratory Evaluations     
Biochemistry  X X X 
Hematology  X X X 
Tacrolimus C 0 X X X 
*For SVW24, SVW36, and SVW52: Bronchoscopi[INVESTIGATOR_409426] a window of +/ - 28 days.   
 